TICKERNERD
Menu
CTXRCTXRHealthcare · Biotechnology

CTXR Stock Forecast: Citius Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.58
−0.68% on the day

The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +588.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.9M
Ticker Nerd rank
21 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$1.5M
Operating income−$10.0M
Net income−$11.9M
Free cash flow−$8.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
−19.3%
YTD
−25.2%
1Y
−51.6%
From 52W high
−68.1%
From 52W low
+20.8%
$0.48
$1.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTXR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Citius Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Quality
68
Growth
38
Accruals
38
Revisions
31
Volatility
23
Momentum
22
Value
21
Issuance
11

Size (90): Smaller than most of the companies we track.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTXR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTXR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26CTXRHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +588.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.AssumesBuy$4.00
11 Mar 2026D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
13 Aug 2025D. Boral CapitalMaintainsBuy—
30 June 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
9 June 2025D. Boral CapitalMaintainsBuy—
23 May 2025Maxim GroupDowngradeHold—
15 May 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
7 Jan 2025D. Boral CapitalMaintainsBuy—
30 Dec 2024D. Boral CapitalUpgradeBuy—
22 Nov 2024D. Boral CapitalDowngradeHold—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024D. Boral CapitalMaintainsBuy—
19 Aug 2024EF HuttonMaintainsBuy—
8 Aug 2024EF HuttonMaintainsBuy—
5 Aug 2024EF HuttonMaintainsBuy—
15 July 2024EF HuttonInitiatesBuy—
31 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTXR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CTXR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Citius Pharmaceuticals, Inc. returned −51.6% against +17.5% for the S&P 500, dividends included.

CTXR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Oct 25Jan 26Apr 26Jul 26CTXRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTXR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Citius Pharmaceuticals, Inc. (CTXR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
0.2×

Cheaper than 89% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−10.4%

Higher than 15% of US stocks

Earnings growth (YoY)
—
Gross margin
67.1%

Higher than 80% of US stocks

Operating margin
−670.2%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.1%

Higher than 16% of US stocks

Return on assets
−26.6%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Citius Pharmaceuticals, Inc. (CTXR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Citius Pharmaceuticals, Inc. has a market value of $15.9M and an enterprise value of $15.4M.

  • Revenue in the twelve months to 30 June 2026: $7.1M. The latest quarter shrank 10.4% year on year.

  • Net income over the same four quarters: −$58.2M, a −818.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$34.9M.

  • Shares outstanding: 27.5M.

  • Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Citius Pharmaceuticals, Inc. employs 23 people — $309K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CTXR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTXRCitius Pharmaceuticals, Inc.$15.9M
21
BCDABioCardia, Inc.$16.1M
42
PASGPassage Bio, Inc.$16.1M
43
PDSBPDS Biotechnology Corp.$16.1M
70
ENLVEnlivex Ltd.$16.2M
40
AEONAEON Biopharma, Inc.$16.3M
51
BIVIBioVie, Inc.$16.3M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Citius Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTXR news & analysis

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

PRNewsWire · 3 Sept 2026neutral

Citius Pharmaceuticals announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in September 2026.

Why it matters — CTXR watchers would care because the company's leadership will be directly engaging with investors at two industry conferences, offering visibility into the company's presentation to the investment community.

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026neutral

Citius Pharmaceuticals reported fiscal third quarter 2026 financial results, noting $7.1 million in revenue for the first nine months from commercial sales of LYMPHIR, $17 million in cash as of June 30, 2026, and an expanded LYMPHIR commercial and medical affairs presence nationwide. The company also provided a business update on its majority-owned subsidiary, Citius Oncology.

Why it matters — The update highlights LYMPHIR's commercial traction and the company's cash position, giving CTXR watchers a current snapshot of the business.

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026positive

Citius Oncology, Inc., a majority-owned subsidiary of Citius Pharmaceuticals, reported fiscal third quarter 2026 financial results and provided a business update. The company reported $7.1 million in revenue for the first nine months of fiscal 2026 as the launch of LYMPHIR progresses, with strong institutional demand driving growth in total vials ordered and the number of institutions ordering LYMPHIR, which has been ordered by 44 institutions since launch.

Why it matters — As a majority-owned subsidiary of CTXR, Citius Oncology's LYMPHIR launch progress and reported revenue indicate how the commercial-stage product is performing for the parent company's watchers.

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

PRNewsWire · 12 Aug 2026neutral

Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D. as an independent director.

Why it matters — Since Citius Oncology is a majority-owned subsidiary of Citius Pharma, changes to its board leadership are relevant to CTXR shareholders following the subsidiary's governance.

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

PRNewsWire · 5 Aug 2026positive

Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, reported commercial momentum for its cancer treatment LYMPHIR, noting new institutional accounts ordering the drug increased 78% quarter over quarter, near-universal payer coverage expanding market access, and an initial cutaneous T-cell lymphoma market currently exceeding $400 million.

Why it matters — Since Citius Pharma holds a majority stake in Citius Oncology, strength in LYMPHIR's commercial rollout (institutional ordering and payer coverage) bears directly on CTXR shareholders.

FAQ

Frequently asked questions about CTXR stock

What is the CTXR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTXR stock a buy right now?

Of the 1 analysts covering Citius Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Pharmaceuticals, Inc. 21 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTXR?

As at 12 Sept 2026, Citius Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will CTXR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +588.5% from the last close, and Ticker Nerd's factor model ranks Citius Pharmaceuticals, Inc. 21 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTXR stock forecast for 2030?

No analyst covering Citius Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CTXR stock performed over the past year?

Citius Pharmaceuticals, Inc. returned -51.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Citius Pharmaceuticals, Inc. do?

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs.

What is the latest news on CTXR?

The most recent item we track (PRNewsWire, 3 Sept 2026): "Citius Pharmaceuticals to Participate in September 2026 Investor Conferences". Citius Pharmaceuticals announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in September 2026.

Company

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products for specialized medical needs. Citius Pharmaceuticals, Inc. concentrates on areas such as oncology, anti-infectives, adjunct cancer care, prescription products, and stem cell therapy. Its current portfolio includes LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, along with late-stage programs such as Mino-Lok for catheter-related bloodstream infections and Halo-Lido for hemorrhoid relief. The company also advances other product candidates aimed at hospital, oncology, and acute-care settings. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals, Inc. plays a role in bringing niche therapies and treatment options to patients and healthcare providers in markets with unmet clinical needs.

CEO Mr. Leonard L. Mazur · 23 employees · United States · https://citiuspharma.com